★ Genitourinary / Cancer
Bladder Cancer VA Rating
38 CFR § 4.115b (rated analogous to DC 7528)
Overview
Added as PACT Act presumptive in 2022 for qualifying burn pit / airborne hazard exposure.
Active malignancy = 100%; six months after treatment ends, residuals are rated under voiding dysfunction or renal dysfunction.
In Depth
Bladder cancer (urothelial carcinoma) was added as a PACT Act presumptive in 2022 for veterans who served in covered locations during qualifying periods (38 USC § 1119, implemented at 38 CFR § 3.320). Covered locations include the Southwest Asia theater of operations and Afghanistan/Djibouti/Egypt/Jordan/Lebanon/Syria/Yemen/Uzbekistan after September 11, 2001, plus other airborne hazard locations.
During active malignancy and for six months after completion of treatment (surgery, chemotherapy, radiation, BCG immunotherapy), the cancer is rated 100% under 38 CFR § 4.115b, by analogy to Diagnostic Code 7528. Six months after treatment ends, VA conducts a mandatory examination and rates the residuals — most often voiding dysfunction, urinary frequency, or obstructed voiding under § 4.115a.
Urothelial carcinoma frequently recurs. Each recurrence triggers a new 100% rating cycle (active treatment + 6 months) without needing to refile a claim — though the veteran should report the recurrence to VA to ensure rerating. Long-term residuals after multiple TURBT (transurethral resection) procedures often include chronic cystitis, urinary frequency, and reduced bladder capacity.
Direct service connection (non-PACT-Act) remains available for veterans with documented exposure to known carcinogens — diesel exhaust, JP-8/JP-5 jet fuel, ionizing radiation, or industrial solvents (TCE, PCE) — when a nexus opinion links exposure to the cancer.
How to Establish Service Connection
- Presumptive (PACT Act) for qualifying veterans.
- Direct service connection for documented in-service carcinogen exposure.
Rating Criteria
Paraphrased from 38 CFR § 4.115b (rated analogous to DC 7528)
| Rating | Criteria |
|---|---|
| 100% | During active malignancy and for 6 months following completion of treatment. |
| Variable | After 6 months: rated on residuals (voiding dysfunction, renal dysfunction, or recurrence). |
See what each percentage pays in 2026 and how it combines with your current rating →
Evidence Checklist
- Pathology report.
- Treatment records (TURBT, BCG, chemo).
- Burn pit registry enrollment.
- Deployment records.
Evidence Templates
Common formats of evidence the VA looks for in this type of claim. These describe what the documents typically include — they are not legal forms or medical opinions, and Oakridge Claims does not draft them.
Cystoscopy & Pathology Reports
Tissue diagnosis confirming urothelial carcinoma, with stage and grade.
Treatment Timeline
Dates of TURBT procedures, BCG instillations, chemo/radiation cycles, and completion of all active treatment.
Voiding Diary
Two-week log of daytime/nighttime voiding frequency, pad changes, and urgency episodes — primary evidence for residuals rating under § 4.115a.
Burn Pit / Exposure Documentation
DD-214, deployment orders, or VA Airborne Hazards and Open Burn Pit Registry enrollment confirming covered service.
Evidence VA Commonly Cites in These Claims
Descriptive summary of evidence types frequently referenced in rating decisions for this condition. Not a checklist of actions to take — every claim is decided on its own facts.
- ★Confirm the veteran's deployment locations and dates match a PACT Act covered location and qualifying period. Mismatches are a common reason for presumptive denials.
- ★Submit pathology reports identifying urothelial carcinoma, including stage (Ta, T1, T2+) and grade (low vs high).
- ★Document the full treatment timeline: TURBT operative reports, BCG instillation dates, chemo/radiation cycles, and completion date — the 100% rating runs from completion plus 6 months.
- ★For the residuals rating after the 6-month window, urology notes documenting urinary frequency (daytime/nighttime), pad use, obstructed voiding, or urinary tract infections drive the voiding dysfunction rating tier under § 4.115a.
- ★Report every recurrence promptly to trigger a new 100% rating cycle — VA does not automatically know when a recurrence is diagnosed.
Illustrative Scenarios
These are hypothetical educational examples — not actual case results, predictions, or guarantees of outcomes.
Post-9/11 burn pit veteran diagnosed with bladder cancer
Army veteran with 12 months in Iraq (2007–2008) diagnosed with T1 high-grade urothelial carcinoma in 2024. PACT Act presumptive service connection granted; 100% rating from diagnosis date through 6 months after completion of BCG immunotherapy. At the 6-month exam, residuals included urinary frequency every 2 hours daytime and 2x nightly — rated 20% under § 4.115a.
Vietnam-era veteran with non-presumptive cancer
Veteran with documented Agent Orange exposure (Vietnam, 1969) initially denied because bladder cancer is not on the Agent Orange presumptive list. Direct service connection granted on appeal with a private nexus opinion citing the IARC monograph on bladder cancer carcinogens present in defoliant formulations.
Common pitfalls VA sees
- Failing to report a recurrence — without notice, VA does not restart the 100% cycle even though the regulation entitles the veteran to it.
- Letting the 6-month post-treatment exam happen without bringing voiding logs or pad-use records, leaving residuals undocumented.
- Filing only for the cancer and missing secondary claims (erectile dysfunction after radical cystectomy, depression, sleep impairment from nocturia).
- Assuming bladder cancer is presumptive for all veterans — PACT Act requires service in a covered location during a qualifying period.
Common Secondary Conditions
Conditions frequently service-connected as secondary to Bladder Cancer:
Frequently Asked Questions
Have a Bladder Cancer claim or denial?
Four fields. A VA-accredited claims agent reviews it and responds within 3–5 business days. Contingent fees apply only to awarded past-due benefits on appeals — never on initial claims.
Requesting a consultation does not create representation and is not a guarantee of any outcome. Representation begins only after a written fee agreement and VA Form 21-22a are signed.
Educational content only — not legal advice and not medical advice. Rating criteria on this page are summarized in plain English from 38 CFR Part 4; consult VA.gov or the current Code of Federal Regulations for official criteria. This page provides general education about how the VA rates this condition; it is not individualized advice, does not establish a representation relationship, and should not be used to self-diagnose, self-treat, or decide a course of action without speaking to a qualified clinician and a VA-accredited representative. Outcomes depend on each veteran's individual facts, evidence, and the adjudicator's judgment; no specific rating, effective date, or other result is guaranteed. Oakridge Claims is a private business and is not affiliated with, endorsed by, or operated by the US Department of Veterans Affairs.